Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Huabo Biopharm Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Signed informed consent form
2. Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
3. No prior systemic therapy for inoperable locally advanced or metastatic TNBC
4. ECOG performance status of 0 or 1
5. Life expectancy ≥ 12 weeks
6. Measurable disease, as defined by RECIST v1.1
You may not be if
1. History of severe allergic diseases, allergic history of serious drugs (including unlisted test drugs) or known allergic to any component of this test drug;
2. Previously received any antibody or inhibitor therapy targeting PD-1/PD-L1 or VEGF;
3. Uncontrollable or symptomatic central nervous system (CNS) metastasis;
4. Pregnancy or lactation;
5. Those who have active infection
6. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
Clareo Health | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
